dc.contributor.author |
Xu, Maoling |
|
dc.contributor.author |
Zhang, Cun |
|
dc.contributor.author |
Yu, Xiuzhen |
|
dc.contributor.author |
Zhu, Lele |
|
dc.contributor.author |
Tan, Hong |
|
dc.contributor.author |
Wang, Cong |
|
dc.contributor.author |
Zhao, Lingshi |
|
dc.contributor.author |
Zhao, Zhihua |
|
dc.date.accessioned |
2022-10-20T10:12:36Z |
|
dc.date.available |
2022-10-20T10:12:36Z |
|
dc.date.issued |
2021-01-16 |
|
dc.identifier.issn |
1011-601X |
|
dc.identifier.uri |
http://142.54.178.187:9060/xmlui/handle/123456789/13495 |
|
dc.description.abstract |
: This study aimed to investigate the application effect of tirofiban on percutaneous coronary intervention (PCI)
in patients with acute coronary syndrome (ACS) and its postoperative effect on C-X-C motif chemokine ligand 16
(CXCL16) level and myocardial perfusion. A total of 50 cases of patients diagnosed with acute coronary syndrome and
treated in Sunshine Union Hospital (Weifang, China) were included in group A and 30 cases of healthy subjects
underwent physical examination in our hospital during the same period were enrolled in group B. Tirofiban was used in
group A patients during PCI. Clinical efficacy evaluation criteria were used to evaluate the efficacy after treatment. The
level of CXCL16 in serum before and after treatment was detected by qRT-PCR. Receiver operating characteristic
(ROC) curve was drawn to analyze the value of C-X-C Motif Chemokine Ligand in diagnosing ACS. Before treatment,
CXCL16 level in group A was significantly higher than that in group B (p<0.001). After treatment, patients in TMPG
grade 3 in group A were significantly increased (p<0.001). Tirofiban could improve myocardial perfusion in patients
with ACS after PCI, reduce adverse events and CXCL16 levels. Serum CXCL16 is expected to be a potential diagnostic
and therapeutic predictor of ACS. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Karachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachi |
en_US |
dc.subject |
Tirofiban |
en_US |
dc.subject |
acute coronary syndrome |
en_US |
dc.subject |
PCI |
en_US |
dc.subject |
CXCL16 |
en_US |
dc.subject |
myocardial perfusion |
en_US |
dc.title |
Application effect of tirofiban on percutaneous coronary intervention in patients with acute coronary syndrome and its postoperative effect on C-X-C motif chemokine ligand 16 level and myocardial perfusion |
en_US |
dc.type |
Article |
en_US |